Skip To Main Content
Barbara Oliviero on Muck Rack

Barbara Oliviero

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Inhibition of the SerpinB3/protease-activated receptor 2 axis reduces liver cancer development and affects lipid metabolism

|
By Pietro Guerra, Gianmarco Villano, Claudia M. Rejano-Gordillo, Clàudia Gil-Pitarch, Mariagrazia Ruvoletto, Alessandra Biasiolo, Santina Quarta, Irene González-Recio, Naroa Goikoetxea-Usandizaga, Arantza Sanz-Parra, Alessandro Gambella, Silvia De Siervi, Barbara Oliviero, Stefania Mantovani, Silvia Cagnin, Andrea Martini, Cristian Turato, Stefania Cannito, Maria Guido Verified, Maurizio Parola, Maria Luz Martinez-Chantar, Patrizia Pontisso, L. Estefanía Zapata-Pavas, Patricia Peña- SanFelix, Jon Ander Barrenechea-Barrenechea, Jessica Nurcis
| Nature Verified
Abstract MASLD and HCC are increasing challenges in hepatology. 1-Piperidinepropionic acid (1-PPA), a protease-activated receptor 2 (PAR2) inhibitor, downregulates SerpinB3, a molecule involved in fibrosis and HCC. This study investigates the effects of 1-PPA on lipid accumulation and HCC development. 1-PPA was employed in primary hepatocytes and human liver organoids cultured with steatogenic compounds and lomitapide, a VLDL-formation inhibitor.
Open in Who Shared Issue with article?

Selection of Functional Glycoforms in Anti-SARS-CoV-2 Human IgG1 Monoclonal Antibodies by FcγRIIIa Affinity Chromatography and Mass Spectrometry Click to copy article link Article link copied!

|
By Barbara Oliviero, Sunil Kumar, Daniela Conteianni
| dx.doi.org
1. Introduction Click to copy section linkSection link copied! Coronavirus disease 2019 (COVID-19), declared pandemic by the World Health Organization in March 2020, has resulted in over 777 million cases and more than 7 million deaths as of May 2025 (1) and highlighted the need for multidisciplinary approaches for the development of efficient biotherapeutic drugs for this and other viral respiratory diseases.
Open in Who Shared Issue with article?

Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host’s Immunity

|
By Mario U Mondelli, Barbara Oliviero, Stefania Mantovani, Sabrina Ottolini
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 4 articles